This meta-analysis examined existing evidence on the efficacy of glucagon-like peptide-1 receptor agonists on the management of non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.